Concert Pharmaceuticals Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer. The company’s clinical-stage product candidates include AVP-786, which is in Phase II clinical trial for the treatment of neurologic and psychiatric disorders, including pain, behavioral disorders, mood disorders, and movement disorders; CTP-499 that is in Phase II clinical trial for chronic kidney disease in patients with type 2 diabetes; and CTP-354, which is in Phase I clinical trial to spasticity associated with spinal cord injury and multiple sclerosis.
